Naᵥ channels — research review 2

...and these Naᵥ channels are fascinating because they're essentially the gatekeepers for pain signals. When they're activated, they propagate that signal, telling your brain something hurts.

So, if you can modulate these channels, you could potentially manage pain. But what's the connection to aging and overall mortality? That seems like a big leap from just pain signals.

It's less about the channels directly "causing" death and more about the impact of chronic, unrelieved pain. We know now that persistent pain, especially conditions like painful diabetic neuropathy, is linked to accelerated biological aging.

Accelerated biological aging? How do we even measure that?

Studies, like one in GeroScience from 2025, have shown that painful diabetic neuropathy is associated with accelerated epigenetic aging and telomere shortening compared with painless neuropathy. So, chronic pain, mediated by these channels, can genuinely speed up the aging process at a cellular level.

That's a powerful connection. So, then the drugs that target these Naᵥ channels—are they the solution? Do they slow this aging process by relieving pain?

That’s a crucial question, and it's where things get complex. While these drugs can be very effective for specific types of neuropathic pain, their long-term impact on all-cause mortality and biological aging isn't fully established.

So, we know unrelieved pain accelerates aging, but we don't yet know if treating that pain with these specific medications reverses or even halts that acceleration.

Precisely. For individuals suffering from severe, debilitating pain, these medications can offer significant relief and improve quality of life. But the broader, long-term safety profile regarding overall survival and the downstream effects on biological aging for the general population, or even those without severe pain, remains an area of ongoing research and uncertainty.